Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Statistics

Total Valuation

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. has a market cap or net worth of CNY 16.30 billion. The enterprise value is 15.02 billion.

Market Cap	16.30B
Enterprise Value	15.02B

Important Dates

The next estimated earnings date is Saturday, April 19, 2025.

Earnings Date	Apr 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. has 264.71 million shares outstanding. The number of shares has increased by 6.08% in one year.

Current Share Class	n/a
Shares Outstanding	264.71M
Shares Change (YoY)	+6.08%
Shares Change (QoQ)	-2.77%
Owned by Insiders (%)	29.35%
Owned by Institutions (%)	26.49%
Float	151.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	33.36
PB Ratio	12.51
P/TBV Ratio	13.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-86.12
EV / Sales	30.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-680.30

Financial Position

The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.71.

Current Ratio	1.95
Quick Ratio	1.79
Debt / Equity	0.71
Debt / EBITDA	n/a
Debt / FCF	-41.81
Interest Coverage	-10.80

Financial Efficiency

Return on equity (ROE) is -12.48% and return on invested capital (ROIC) is -7.84%.

Return on Equity (ROE)	-12.48%
Return on Assets (ROA)	-6.50%
Return on Capital (ROIC)	-7.84%
Revenue Per Employee	563,381
Profits Per Employee	-201,149
Employee Count	867
Asset Turnover	0.17
Inventory Turnover	0.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.23% in the last 52 weeks. The beta is 0.62, so Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+15.23%
50-Day Moving Average	65.05
200-Day Moving Average	57.86
Relative Strength Index (RSI)	41.47
Average Volume (20 Days)	2,103,618

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Suzhou Zelgen Biopharmaceuticals Co.,Ltd. had revenue of CNY 488.45 million and -174.40 million in losses. Loss per share was -0.66.

Revenue	488.45M
Gross Profit	451.45M
Operating Income	-302.88M
Pretax Income	-194.42M
Net Income	-174.40M
EBITDA	-267.87M
EBIT	-302.88M
Loss Per Share	-0.66

Full Income Statement

Balance Sheet

The company has 2.20 billion in cash and 923.07 million in debt, giving a net cash position of 1.28 billion or 4.84 per share.

Cash & Cash Equivalents	2.20B
Total Debt	923.07M
Net Cash	1.28B
Net Cash Per Share	4.84
Equity (Book Value)	1.30B
Book Value Per Share	4.92
Working Capital	1.25B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 63.12 million and capital expenditures -85.19 million, giving a free cash flow of -22.08 million.

Operating Cash Flow	63.12M
Capital Expenditures	-85.19M
Free Cash Flow	-22.08M
FCF Per Share	-0.08

Full Cash Flow Statement

Margins

Gross margin is 92.43%, with operating and profit margins of -62.01% and -35.70%.

Gross Margin	92.43%
Operating Margin	-62.01%
Pretax Margin	-39.80%
Profit Margin	-35.70%
EBITDA Margin	-54.84%
EBIT Margin	-62.01%
FCF Margin	n/a

Dividends & Yields

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.08%
Shareholder Yield	-6.08%
Earnings Yield	-1.07%
FCF Yield	-0.14%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. has an Altman Z-Score of 4.23.

Altman Z-Score	4.23
Piotroski F-Score	n/a